Open AccessFOLFIRINOX as First-line Chemotherapy in Japanese Patients Suffering from Metastatic Pancreatic Cancer (KOBE FOLFIRINOX Study)
Author(s) -
Yukimasa Hatachi,
Sharad R Mohan,
Takeshi Kotake,
Hironaga Satake,
Yoshihiro Okita,
Hisateru Yasui,
Akihito Tsuji
Publication year - 2022
Publication title -
cancer diagnosis and prognosis
Language(s) - English
Resource type - Journals
ISSN - 2732-7787
DOI - 10.21873/cdp.10083
Subject(s) - folfirinox , irinotecan , oxaliplatin , medicine , fluorouracil , chemotherapy , bolus (digestion) , pancreatic cancer , oncology , gastroenterology , cancer , colorectal cancer
FOLFIRINOX (oxaliplatin, irinotecan, 5-fluorouracil, and leucovorin) combination chemotherapy is the gold-standard therapy for advanced pancreatic cancer. In this study, FOLFIRINOX dosages for Japanese patients were established enabling FOLFIRINOX therapy optimization for efficient use.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom